2051 Ringwood Avenue
San Jose, CA 95131
United States
408 457 3700
https://www.ranitherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 140
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Mir A. Imran | Executive Chairman | 80k | N/A | 1956 |
Mr. Talat Imran | CEO & Director | 450k | N/A | 1982 |
Mr. Svai S. Sanford | Chief Financial Officer | 416k | N/A | 1970 |
Dr. Mir Hashim | Chief Scientific Officer | 416k | N/A | 1960 |
Mr. Eric Groen | General Counsel | N/A | N/A | 1971 |
Ms. Bella Vazquez | Vice President of Human Resources | N/A | N/A | N/A |
Ms. Kate McKinley M.B.A. | Chief Business Officer | N/A | N/A | 1977 |
Ms. Arvinder Dhalla | Vice President of Clinical Development | N/A | N/A | N/A |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Rani Therapeutics Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.